Download MendeleyGranzyme B-mimetic nanozyme for nanovesicle targeted anticancer applications.
Hu, X., Liu, Q., Kang, H., Zhao, M., Zhou, Z., Li, Y., Peng, W., Qi, T., Liu, R., Jiao, L., Zhuang, J., Liu, Y., Mann, S., Huang, X.(2026) Nat Commun 17
- PubMed: 41587995
- DOI: https://doi.org/10.1038/s41467-026-68773-x
- Primary Citation Related Structures:
9JGO, 9JGP - PubMed Abstract:
Cytotoxic T lymphocytes play a crucial role in anti-tumour immunity, with granzyme B (GrB) being a decisive factor in this process. Developing a GrB-based delivery system to mimic T cell-based immunotherapy holds promise but remains challenging. Here, we present an artificial metalloenzyme (nanozyme) with GrB-like protease activity capable of inducing caspase-dependent cell apoptosis. The nanozyme is based on the site-specific binding of Pd(II) ions to recombinant human heavy chain apo-ferritin nanocages to generate a binuclear catalytic centre consisting of two Pd atoms with bridging cysteine ligands, monodentate methionine and histidine residues, and two water molecules. We show that encapsulation of the Pd-ferritin complex within membrane-fused lipid nanoparticles comprising surface-displayed single-chain antibodies affords GrB-mimicking nanozyme-based nanovesicles capable of receptor-mediated delivery of the nanozyme into the cytoplasm of tumour cells and induction of caspase-dependent apoptosis. This study provides valuable insights into the construction of nano-delivery systems with artificial GrB activity and presents a promising therapeutic option for solid tumours.
- Key Laboratory of Bioactive Materials for the Ministry of Education, College of Life Sciences, State Key Laboratory of Medicinal Chemical Biology, and Frontiers Science Centre for Cell Responses, Nankai University, Tianjin, China.
Organizational Affiliation:
